Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study

Clinical Therapeutics

Volumn 24, Issue 11, 2002, Pages 1871-1886

  Simon, James A ^a,b   Lewiecki, E Michael ^c   Smith, Mary E ^d   Petruschke, Richard A ^d   Wang, Lixia ^d   Palmisano, Joanne J ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health Research Center   (United States)

^c NM Clin Res/Osteoporosis Ctr Inc   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Bisphosphonates; Compliance; Once weekly dosing; Osteoporosis; Preference

Indexed keywords

ALENDRONIC ACID;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG PREFERENCE; DRUG TOLERABILITY; DYSPEPSIA; EPIGASTRIC BURNING; ESOPHAGUS INJURY; FEMALE; FLATULENCE; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 0036860290     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80085-6     Document Type: Article

References (35)

1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
2. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43-49.
3. Svensson S, Kjellgren KI, Ahlner J, Säljö R. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76:157-163.
4. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence? Curr Hypertens Rep. 2000;2:515-524.
5. Feldman R, Bacher M, Campbell N, et al. Adherence to pharmacologic management of hypertension. Can J Public Health. 1998;89:I16-I18.
6. McClung B, McClung M. Pharmacologic therapy for the treatment and prevention of osteoporosis. Nurs Clin North Am. 2001;36:433-440.
7. Watts NB. Postmenopausal osteoporosis. Obstet Gynecol Surv. 1999;54:532-538.
8. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443.
9. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendrohate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Research Group. Lancet. 1996;348:1535-1541.
11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
12. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in post-menopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis Int. 1999;9:461-468.
13. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124.
14. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Stucly Group. N Engl J Med. 1998;339:292-299
15. ®. 55th Ed. Montvale, NJ: Medical Economics Co; 2001:1930-1936.
16. Mersfelder T, Armitstead JA, Ivey MF, Cedars M. A medication use evaluation of alendronate: Compliance with administration guidelines. Pharm Pract Manag Q. 1999;18:50-58.
17. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: Rationale and plan for clinical assessment. Clin Ther. 2000;22:15-28.
18. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano). 2000;12:1-12.
19. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
20. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
21. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
22. Greenspan SL, Field-Munves EM, Tonino RP, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002;77:1044-1052.
23. Gart JJ. An exact test for comparing matched proportions in crossover designs. Biometrika. 1969;56:75-80.
24. Prescott RJ. The comparison of success rates in crossover trials in the presence of an order effect. Appl Statist. 1981;30:9-15.
25. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12:153-157.
26. Murphy J, Coster G. Issues in patient compliance. Drugs. 1997;54:797-800.
27. Cameron C. Patient compliance: Recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. J Adv Nurs. 1996;24:244-250.
28. Carmen Luciano M, Herruzo J. Some relevant components of adherence behavior. J Behav Ther Exp Psychiatry. 1992;23:117-124.
29. Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Community Health. 1980;6:113-135.
30. Sclar DA. Improving medication compliance: A review of selected issues. Clin Ther. 1991;13:436-440.
31. Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost. 2001;7:33-37.
32. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med. 1999;93:763-769.
33. Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998;4:1421-1430.
34. Venturini F, Nichol MB, Sung JC, et al. Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study. Ann Pharmacother. 1999;33:281-288.
35. Colley CA, Lucas LM. Polypharmacy: The cure becomes the disease. J Gen Intern Med. 1993;8:278-283.